In this Review, Teixeira et al. discuss emerging strategies for developing and improving engineered-cell therapies. They outline progress from ex vivo engineered autologous cells to in vivo reprogramming, advances in delivery systems and the remaining translational barriers.
- Ana Palma Teixeira
- Dominique Aubel
- Martin Fussenegger